Literature DB >> 9973531

IgG subclass switching is associated with the severity of experimental autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein peptide in NOD mice.

M Ichikawa1, C S Koh, Y Inaba, C Seki, A Inoue, M Itoh, Y Ishihara, C C Bernard, A Komiyama.   

Abstract

We have recently shown that a single dose of the myelin oligodendrocyte glycoprotein (MOG) peptide 35-55 produces a relapsing-remitting demyelinating disease similar to multiple sclerosis (MS) in Lewis rats. In this study we have assessed the possibility that a subclass of anti-MOG35-55 antibodies influences the clinical outcome of these diseases by examining the classes and isotypes of anti-MOG35-55 antibody produced during the course of MOG35-55-induced demyelinating disease in NOD mice. Following immunization, 7 of the 21 injected mice had only mild diseases, while the 14 others had severe progressive and/or relapsing-remitting diseases. There were no differences in anti-MOG35-55 IgG, IgA, IgM, IgG1, IgG2a, and IgG3 antibody titers between the severe and mild symptoms groups. High levels of IgG2b antibody to MOG35-55 were detected in all mice with severe symptoms. In contrast, none of the mice which contracted a mild disease produced anti-MOG35-55 IgG2b. These results suggest that in NOD mice, the IgG2b antibody response to MOG35-55 is associated with the severity of this MS-like demyelinating disease. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973531     DOI: 10.1006/cimm.1998.1414

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

Review 1.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Genistein prevention of hyperglycemia and improvement of glucose tolerance in adult non-obese diabetic mice are associated with alterations of gut microbiome and immune homeostasis.

Authors:  Guannan Huang; Joella Xu; Daniel E Lefever; Travis C Glenn; Tamas Nagy; Tai L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2017-04-12       Impact factor: 4.219

3.  Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis.

Authors:  V H Secor; W E Secor; C A Gutekunst; M A Brown
Journal:  J Exp Med       Date:  2000-03-06       Impact factor: 14.307

4.  Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.

Authors:  J L McQualter; R Darwiche; C Ewing; M Onuki; T W Kay; J A Hamilton; H H Reid; C C Bernard
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

5.  Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis.

Authors:  D R Huang; J Wang; P Kivisakk; B J Rollins; R M Ransohoff
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

6.  Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis.

Authors:  Conan K Wang; Christian W Gruber; Maša Cemazar; Christopher Siatskas; Prascilla Tagore; Natalie Payne; Guizhi Sun; Shunhe Wang; Claude C Bernard; David J Craik
Journal:  ACS Chem Biol       Date:  2013-11-07       Impact factor: 5.100

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.